The new drug called AN12855 has several advantages over Isoniazid as Isoniazid requires conversion to its active form by a Mycobacterial enzyme KatG in order to kill the pathogen which creates some problems. In some M. tuberculosis KatG is nonfunctional. That does not make M. tuberculosis any less pathogenic but it prevents the drug from working. Consequently this creates an easy avenue for the development of drug resistance. In the study the new drug showed a much lower tendency to develop resistance and it remains in the tissues where the Mycobacterium tuberculosis bacteria reside for longer killing them more effectively.